Therapy: The role of liquid biopsies to manage and predict PRRT for NETs.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers.Journal of neuroendocrinology · 2025
   Review
2. The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms.Cancers · 2024
   Review
3. Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023
   Article
4. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.European journal of nuclear medicine and molecular imaging · 2020
   Article
5. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors.Advances in medical sciences · 2020
   Review
6. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.Frontiers in oncology · 2020
   Review
7. The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors.Scientific reports · 2019
   Article
8. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.Drugs · 2019
   Review
9. The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors.Endocrinology and metabolism clinics of North America · 2018
   Review
10. PRRT genomic signature in blood for prediction ofEuropean journal of nuclear medicine and molecular imaging · 2018
    Article
11. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.Cancer genomics & proteomics
    Article

Corrections and comments

• Comment on
  Phase 3 Trial of2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as